Opus Genetics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Opus Genetics, Inc. (IRD) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$1.40 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.
Discontinued › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2020-10-29
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2020-09-30 was -$1.40M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2020-06-30 was -$2.51M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2020-03-31 was -$586.77K.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2019-12-31 was -$1.87M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2019 was -$8.64M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2018 was -$14.37M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2017 was -$25.29M.
- Opus Genetics, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was -$9.31M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 132 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 135 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 138 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 141 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 144 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 147 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 150 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 153 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 156 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | -$1.40M 10-Q · filed 2020-10-29 | -$3.91M derived: sum of 2 quarters · filed 2020-10-29 | -$4.50M 10-Q · filed 2020-10-29 | -$6.37M derived: sum of 4 quarters · filed 2020-10-29 | |||||||||
| 2020-06-30 | -$2.51M 10-Q · filed 2020-08-14 | -$3.10M 10-Q · filed 2020-08-14 | -$4.97M derived: sum of 3 quarters · filed 2020-08-14 | -$6.93M derived: sum of 4 quarters · filed 2020-10-29 | |||||||||
| 2020-03-31 | -$586.77K 10-Q · filed 2020-05-07 | -$2.46M derived: sum of 2 quarters · filed 2020-05-07 | -$4.41M derived: sum of 3 quarters · filed 2020-10-29 | -$6.88M derived: sum of 4 quarters · filed 2020-10-29 | |||||||||
| 2019-12-31 | -$1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$3.83M derived: sum of 2 quarters · filed 2020-10-29 | -$6.29M derived: sum of 3 quarters · filed 2020-10-29 | -$8.64M 10-K · filed 2020-02-21 | |||||||||
| 2019-09-30 | -$1.96M 10-Q · filed 2020-10-29 | -$4.42M derived: sum of 2 quarters · filed 2020-10-29 | -$6.77M 10-Q · filed 2020-10-29 | -$9.88M derived: sum of 4 quarters · filed 2020-10-29 | |||||||||
| 2019-06-30 | -$2.46M 10-Q · filed 2020-08-14 | -$4.81M 10-Q · filed 2020-08-14 | -$7.92M derived: sum of 3 quarters · filed 2020-08-14 | -$13.26M derived: sum of 4 quarters · filed 2020-08-14 | |||||||||
| 2019-03-31 | -$2.34M 10-Q · filed 2020-05-07 | -$5.46M derived: sum of 2 quarters · filed 2020-05-07 | -$10.80M derived: sum of 3 quarters · filed 2020-05-07 | -$14.64M derived: sum of 4 quarters · filed 2020-05-07 | |||||||||
| 2018-12-31 | -$3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$8.46M derived: sum of 2 quarters · filed 2020-02-21 | -$12.29M derived: sum of 3 quarters · filed 2020-02-21 | -$14.37M 10-K · filed 2020-02-21 | |||||||||
| 2018-09-30 | -$5.34M 10-Q · filed 2019-11-06 | -$9.18M derived: sum of 2 quarters · filed 2019-11-06 | -$11.25M 10-Q · filed 2019-11-06 | -$14.84M derived: sum of 4 quarters · filed 2019-11-06 | |||||||||
| 2018-06-30 | -$3.84M 10-Q · filed 2019-08-07 | -$5.91M 10-Q · filed 2019-08-07 | -$9.51M derived: sum of 3 quarters · filed 2019-08-07 | -$10.54M derived: sum of 4 quarters · filed 2019-08-07 | |||||||||
| 2018-03-31 | -$2.07M 10-Q · filed 2019-05-10 | -$5.67M derived: sum of 2 quarters · filed 2019-05-10 | -$6.71M derived: sum of 3 quarters · filed 2019-05-10 | -$5.76M derived: sum of 4 quarters · filed 2019-05-10 | |||||||||
| 2017-12-31 | -$3.59M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$4.63M derived: sum of 2 quarters · filed 2019-03-07 | -$3.68M derived: sum of 3 quarters · filed 2019-03-07 | -$25.29M 10-K · filed 2019-03-07 | |||||||||
| 2017-09-30 | -$1.04M 10-Q · filed 2018-11-02 | -$91.02K derived: sum of 2 quarters · filed 2018-11-02 | -$21.70M 10-Q · filed 2018-11-02 | -$22.23M derived: sum of 4 quarters · filed 2018-11-02 | |||||||||
| 2017-06-30 | $947.06K 10-Q · filed 2018-08-03 | -$20.66M 10-Q · filed 2018-08-03 | -$21.19M derived: sum of 3 quarters · filed 2018-08-03 | -$24.06M derived: sum of 4 quarters · filed 2018-08-03 | |||||||||
| 2017-03-31 | -$21.61M 10-Q · filed 2018-05-04 | -$22.14M derived: sum of 2 quarters · filed 2018-05-04 | -$25.00M derived: sum of 3 quarters · filed 2018-05-04 | -$26.77M derived: sum of 4 quarters · filed 2018-05-04 | |||||||||
| 2016-12-31 | -$525.48K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$3.39M derived: sum of 2 quarters · filed 2018-03-09 | -$5.16M derived: sum of 3 quarters · filed 2018-03-09 | -$9.31M 10-K · filed 2018-03-09 | |||||||||
| 2016-09-30 | -$2.87M 10-Q · filed 2017-11-03 | -$4.63M derived: sum of 2 quarters · filed 2017-11-03 | -$8.78M 10-Q · filed 2017-11-03 | -$11.63M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2016-06-30 | -$1.77M 10-Q · filed 2017-08-04 | -$5.91M 10-Q · filed 2017-08-04 | -$8.77M derived: sum of 3 quarters · filed 2018-03-09 | -$12.79M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2016-03-31 | -$4.15M 10-Q · filed 2017-05-03 | -$7.00M derived: sum of 2 quarters · filed 2018-03-09 | -$11.03M derived: sum of 3 quarters · filed 2018-03-09 | -$14.26M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2015-12-31 | -$2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$6.88M derived: sum of 2 quarters · filed 2018-03-09 | -$10.11M derived: sum of 3 quarters · filed 2018-03-09 | -$14.38M 10-K · filed 2018-03-09 | |||||||||
| 2015-09-30 | -$4.03M 10-Q · filed 2016-11-04 | -$7.26M derived: sum of 2 quarters · filed 2016-11-04 | -$11.53M 10-Q · filed 2016-11-04 | -$13.74M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2015-06-30 | -$3.23M 10-Q · filed 2016-08-05 | -$7.51M 10-Q · filed 2016-08-05 | -$9.72M derived: sum of 3 quarters · filed 2017-02-24 | -$11.62M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2015-03-31 | -$4.27M 10-Q · filed 2016-05-06 | -$6.48M derived: sum of 2 quarters · filed 2017-02-24 | -$8.39M derived: sum of 3 quarters · filed 2017-02-24 | -$8.19M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2014-12-31 | -$2.21M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | -$4.12M derived: sum of 2 quarters · filed 2017-02-24 | -$3.92M derived: sum of 3 quarters · filed 2017-02-24 | -$18.52M 10-K · filed 2017-02-24 | |||||||||
| 2014-09-30 | -$1.91M 10-Q · filed 2015-11-02 | -$1.71M derived: sum of 2 quarters · filed 2015-11-02 | -$16.31M 10-Q · filed 2015-11-02 | -$19.03M derived: sum of 4 quarters · filed 2016-03-14 | |||||||||
| 2014-06-30 | $194.46K 10-Q · filed 2015-08-07 | -$14.41M 10-Q · filed 2015-08-07 | -$17.13M derived: sum of 3 quarters · filed 2016-03-14 | -$19.27M derived: sum of 4 quarters · filed 2016-03-14 | |||||||||
| 2014-03-31 | -$14.60M 10-Q · filed 2015-05-08 | -$17.32M derived: sum of 2 quarters · filed 2016-03-14 | -$19.46M derived: sum of 3 quarters · filed 2016-03-14 | -$22.57M derived: sum of 4 quarters · filed 2016-03-14 | -$87.41M 10-Q · filed 2014-05-14 | ||||||||
| 2013-12-31 | -$2.72M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$4.86M derived: sum of 2 quarters · filed 2016-03-14 | -$7.97M derived: sum of 3 quarters · filed 2016-03-14 | -$9.50M 10-K · filed 2016-03-14 | -$72.81M 10-K · filed 2014-03-21 | ||||||||
| 2013-09-30 | -$2.14M 10-Q · filed 2014-11-12 | -$5.25M derived: sum of 2 quarters · filed 2014-11-12 | -$6.78M 10-Q · filed 2014-11-12 | -$6.84M derived: sum of 4 quarters · filed 2014-11-12 | -$70.09M 10-Q · filed 2013-11-13 | ||||||||
| 2013-06-30 | -$3.11M 10-Q · filed 2014-08-13 | -$4.64M 10-Q · filed 2014-08-13 | -$4.69M derived: sum of 3 quarters · filed 2014-08-13 | -$7.68M derived: sum of 4 quarters · filed 2014-08-13 | -$67.95M 10-Q · filed 2013-08-12 | ||||||||
| 2013-03-31 | -$1.53M 10-Q · filed 2014-05-14 | -$1.59M derived: sum of 2 quarters · filed 2014-05-14 | -$4.57M derived: sum of 3 quarters · filed 2014-05-14 | -$5.62M derived: sum of 4 quarters · filed 2014-05-14 | -$64.84M 10-Q · filed 2013-05-09 | ||||||||
| 2012-12-31 | -$55.40K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$3.04M derived: sum of 2 quarters · filed 2014-03-21 | -$4.09M derived: sum of 3 quarters · filed 2014-03-21 | -$6.23M 10-K · filed 2014-03-21 | -$63.31M 10-K · filed 2013-03-22 | ||||||||
| 2012-09-30 | -$2.99M 10-Q · filed 2013-11-13 | -$4.03M derived: sum of 2 quarters · filed 2013-11-13 | -$6.17M 10-Q · filed 2013-11-13 | -$5.78M derived: sum of 4 quarters · filed 2013-11-13 | -$63.26M 10-Q · filed 2012-11-08 | ||||||||
| 2012-06-30 | -$1.04M 10-Q · filed 2013-08-12 | -$3.18M 10-Q · filed 2013-08-12 | -$2.79M derived: sum of 3 quarters · filed 2013-08-12 | -$4.26M derived: sum of 4 quarters · filed 2013-08-12 | -$60.27M 10-Q · filed 2012-08-08 | ||||||||
| 2012-03-31 | -$2.14M 10-Q · filed 2013-05-09 | -$1.75M derived: sum of 2 quarters · filed 2013-05-09 | -$3.22M derived: sum of 3 quarters · filed 2013-05-09 | -$9.05M derived: sum of 4 quarters · filed 2013-05-09 | -$59.22M 10-Q · filed 2012-05-09 | ||||||||
| 2011-12-31 | $389.28K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | -$1.08M derived: sum of 2 quarters · filed 2013-03-22 | -$6.91M derived: sum of 3 quarters · filed 2013-03-22 | -$11.34M 10-K · filed 2013-03-22 | |||||||||
| 2011-09-30 | -$1.47M 10-Q · filed 2012-11-08 | -$7.30M derived: sum of 2 quarters · filed 2012-11-08 | -$11.73M 10-Q · filed 2012-11-08 | -$14.34M derived: sum of 4 quarters · filed 2012-11-08 | |||||||||
| 2011-06-30 | -$5.83M 10-Q · filed 2012-08-08 | -$10.27M 10-Q · filed 2012-08-08 | -$12.88M derived: sum of 3 quarters · filed 2012-08-08 | -$12.66M derived: sum of 4 quarters · filed 2012-08-08 | |||||||||
| 2011-03-31 | -$4.44M 10-Q · filed 2012-05-09 | -$7.05M derived: sum of 2 quarters · filed 2012-05-09 | -$6.83M derived: sum of 3 quarters · filed 2012-05-09 | -$10.42M derived: sum of 4 quarters · filed 2012-05-09 | |||||||||
| 2010-12-31 | -$2.61M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | -$2.39M derived: sum of 2 quarters · filed 2012-03-16 | -$5.99M derived: sum of 3 quarters · filed 2012-03-16 | -$14.02M 10-K · filed 2012-03-16 | |||||||||
| 2010-09-30 | $218.89K 10-Q · filed 2011-11-09 | -$3.38M derived: sum of 2 quarters · filed 2011-11-09 | -$11.41M 10-Q · filed 2011-11-09 | ||||||||||
| 2010-06-30 | -$3.60M 10-Q · filed 2011-08-09 | -$11.63M 10-Q · filed 2011-08-09 | |||||||||||
| 2009-12-31 | -$2.90M 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |